AbbVie Inc.’s Pharmacyclics unit and its partner, Johnson & Johnson’s Janssen, won a U.S. court ruling that upheld four patents for the blockbuster cancer drug Imbruvica, blocking Alvogen Pharma US Inc. from selling a generic version of the tablet form until 2036.
U.S. District Judge Colm Connolly, who presided at a trial last year in Wilmington, Delaware, on Thursday rejected Alvogen’s arguments that all four patents should be invalidated. Alvogen had already conceded that its copycat infringes three of the patents, and Connolly found during the trial that the product also infringed a fourth patent for the ...
